论文部分内容阅读
急性髓细胞性白血病(AML)是一种异质性的血液恶性肿瘤,也是发生在成年人中最普遍的急性白血病.过去20年间,对于AML的病理生理学的认识和治疗学等方面取得显著进展尤其是全反式维甲酸(ATRA)和三氧化二砷(As2O3)治疗急性早幼粒细胞性白血病(APL)的成功实践,为许多AML病人带来了生存希望.与此同时,以靶标特异的活性小分子化合物为探针研究重要细胞生命活动规律为主要目的的化学生物学手段,大大地推动了白血病的分子发病学研究和靶向治疗的进步.本文主要以本课题组的工作为重点,对过去10多年中,我国学者在相关研究工作中取得的一些进展作一总结和展望.
Acute myeloid leukemia (AML) is a heterogeneous haematological malignancy and is also the most common acute leukemia that occurs in adults. Over the past two decades, significant advances have been made in the pathophysiology of AML and its therapeutics In particular, the successful practice of ATRA and As2O3 in the treatment of acute promyelocytic leukemia (APL) has brought hope for survival in many AML patients, and at the same time, the target-specific activity is small Molecular chemical compounds as the probe to study the law of important cell life activities as the main purpose of the means of chemical biology, greatly promoted the molecular pathogenesis of leukemia and targeted therapy progress.This paper mainly focus on the work of the group, the past In more than 10 years, some progresses made by Chinese scholars in the related research work are summarized and prospected.